{
    "topic": "healthcare",
    "source": "Scientific American",
    "bias": 1,
    "url": "https://www.scientificamerican.com/article/old-drug-new-tricks-existing-medicines-show-promise-in-fighting-cancer/",
    "title": "Old Drug, New Tricks: Existing Medicines Show Promise in Fighting Cancer",
    "date": "",
    "authors": "Jim Daley",
    "content": "Drugs originally developed to treat diseases ranging from diabetes to alcoholism may have applications in cancer treatment , according to a new study . Researchers tested thousands of existing medications , many of which have already been approved by the U.S. Food and Drug Administration for treating diseases other than cancer , against hundreds of different human cancer cell lines in the lab . The study revealed dozens of newly identified cancer-killing compounds .\nLead author Steven Corsello practices oncology at the Dana-Farber Cancer Institute and researches new cancer drug development at the Broad Institute of the Massachusetts Institute of Technology and Harvard University . He says he regularly treats patients with chemotherapy medications , many of which were developed decades ago . \u201c I deeply appreciate the need for improved and better-tailored cancer therapy , \u201d he says . But new drug development is costly and time-consuming\u2014often requiring years of painstaking research\u2014and potential treatments rarely progress beyond the lab . Even when a medication makes it to clinical trials , it must undergo years of safety testing . And many of those that kill cancer efficiently are also so toxic to test subjects that they are never approved .\nBecause of those limitations , the field of repurposing existing drugs is \u201c really coming to the forefront , \u201d says Jonathan Sexton , a medicinal chemist , who directs the University of Michigan \u2019 s Center for Drug Repurposing and was not involved in the study . \u201c We \u2019 re notoriously very bad at predicting what [ compounds ] are going to be most efficacious against specific cancers , which is why there is a huge attrition rate [ for drugs ] in clinical trials for cancer , \u201d he says . This situation has produced a wealth of medications that may not work for one type of cancer but could work for another type . And as libraries of these compounds continue to grow , Sexton says , a veritable pharmacopeia of treatments is becoming available . \u201c That is where we \u2019 re really leveraging our exposure , \u201d he says .\nAt the Broad Institute , Corsello and his colleagues investigate how drugs affect gene expression\u2014the degree to which genes are turned on or off\u2014to determine whether the compounds have potential applications in cancer treatment . The institute developed a library of more than 1.5 million gene expression profiles from thousands of potential drug molecules , called the Connectivity Map , to guide the search . \u201c In the course of that research , I realized that we were missing many drugs , \u201d including ones that the FDA has already approved for other uses , Corsello says . With that in mind , he and his colleagues at the Broad Institute launched the Drug Repurposing Hub ( DRH ) in 2017 to test existing drugs against various disease models . That open-access library , which researchers anywhere can use for free , now includes more than 6,000 drugs\u2014ranging from aspirin to Zantac\u2014originally developed for other applications .\nRong Xu , a medical bioinformaticist at Case Western Reserve University , who was not involved in the study , says that for \u201c dry \u201d labs\u2014which use computer-generated models to investigate new drug applications\u2014libraries such as the DRH are invaluable . \u201c We \u2019 ll use this as a starting point and correlate and also integrate these data sets with what we know about disease genetics \u201d to design computer algorithms that can identify potential treatment avenues , Xu says .\nIn the new study , published Monday in Nature Cancer , Corsello and his colleagues systematically tested 4,518 compounds from the DRH ( of which 3,350 are already approved for use in the U.S. or Europe ) against 578 cancer cell lines . Most were developed to treat diseases other than cancer ; about a quarter were originally developed for cancer . Using a molecular bar-coding method to keep track of the vast array of cancer cell lines , which employs short sequences of DNA as \u201c bar codes , \u201d the researchers were able to test multiple cancer cell types simultaneously in each Petri dish , speeding the process considerably . In total , the team identified nearly 50 compounds that killed cancer cells and left other cells unscathed .\nThe researchers found 11 different drugs that trigger the same cancer-killing mechanism . These included one previously approved to treat essential thrombocytosis\u2014a blood disorder\u2014as well as progesterone medications . The drugs all appear to work by inducing an interaction between two proteins : PDE3A , which plays a role in regulating blood pressure , and SLFN12 , whose role is not well understood . ( In contrast , many existing cancer treatments merely inhibit enzymes . ) Corsello says the interaction is \u201c an attractive target \u201d for developing new therapies . \u201c The drugs we found are a nice starting point to do that , \u201d he adds .\nOnce a drug shows selective anticancer effects , the next step is to find out how it works . Corsello says the team does so by looking at \u201c everything that \u2019 s known \u201d about the cancer cell lines the drug kills . He lists a battery of genomic features the researchers analyze to determine where and how the killing blow lands , including gene expression , mutation and the number of copies of the gene in the genotype . \u201c Then , using predictive modeling approaches , [ we ] determine predictive biomarkers of response to each of these therapies , \u201d he says .\nOf course , not all of these medications will turn out to work against cancer in humans . Predictive biomarkers can indicate how effective a treatment will be against a particular type of cancer cell line in the lab or how well it can treat a patient in the clinic . \u201c We prioritized drugs for follow-up that had selective [ anticancer ] activity and drugs that had predictive biomarkers from these cell line features , \u201d Corsello says . Medications that can predictably kill certain cancer cells could eventually be tested in patients and predict individuals who could benefit from those treatments .\nCorsello says that the research team plans to add 300 new cancer cell lines and 300 drug compounds to the library . \u201c I think there \u2019 s still a lot that remains to be learned and discovered from this data , \u201d Corsello says . By using technologies such as CRISPR gene editing and screening , \u201c we \u2019 re able to take a drug with promising activity and actually figuring out how it \u2019 s working , which I think is a really promising strategy for the future that may have an impact on drug development . \u201d",
    "content_original": "Drugs originally developed to treat diseases ranging from diabetes to alcoholism may have applications in cancer treatment, according to a new study. Researchers tested thousands of existing medications, many of which have already been approved by the U.S. Food and Drug Administration for treating diseases other than cancer, against hundreds of different human cancer cell lines in the lab. The study revealed dozens of newly identified cancer-killing compounds.\n\nLead author Steven Corsello practices oncology at the Dana-Farber Cancer Institute and researches new cancer drug development at the Broad Institute of the Massachusetts Institute of Technology and Harvard University. He says he regularly treats patients with chemotherapy medications, many of which were developed decades ago. \u201cI deeply appreciate the need for improved and better-tailored cancer therapy,\u201d he says. But new drug development is costly and time-consuming\u2014often requiring years of painstaking research\u2014and potential treatments rarely progress beyond the lab. Even when a medication makes it to clinical trials, it must undergo years of safety testing. And many of those that kill cancer efficiently are also so toxic to test subjects that they are never approved.\n\nBecause of those limitations, the field of repurposing existing drugs is \u201creally coming to the forefront,\u201d says Jonathan Sexton, a medicinal chemist, who directs the University of Michigan\u2019s Center for Drug Repurposing and was not involved in the study. \u201cWe\u2019re notoriously very bad at predicting what [compounds] are going to be most efficacious against specific cancers, which is why there is a huge attrition rate [for drugs] in clinical trials for cancer,\u201d he says. This situation has produced a wealth of medications that may not work for one type of cancer but could work for another type. And as libraries of these compounds continue to grow, Sexton says, a veritable pharmacopeia of treatments is becoming available. \u201cThat is where we\u2019re really leveraging our exposure,\u201d he says.\n\nAt the Broad Institute, Corsello and his colleagues investigate how drugs affect gene expression\u2014the degree to which genes are turned on or off\u2014to determine whether the compounds have potential applications in cancer treatment. The institute developed a library of more than 1.5 million gene expression profiles from thousands of potential drug molecules, called the Connectivity Map, to guide the search. \u201cIn the course of that research, I realized that we were missing many drugs,\u201d including ones that the FDA has already approved for other uses, Corsello says. With that in mind, he and his colleagues at the Broad Institute launched the Drug Repurposing Hub (DRH) in 2017 to test existing drugs against various disease models. That open-access library, which researchers anywhere can use for free, now includes more than 6,000 drugs\u2014ranging from aspirin to Zantac\u2014originally developed for other applications.\n\nRong Xu, a medical bioinformaticist at Case Western Reserve University, who was not involved in the study, says that for \u201cdry\u201d labs\u2014which use computer-generated models to investigate new drug applications\u2014libraries such as the DRH are invaluable. \u201cWe\u2019ll use this as a starting point and correlate and also integrate these data sets with what we know about disease genetics\u201d to design computer algorithms that can identify potential treatment avenues, Xu says.\n\nIn the new study, published Monday in Nature Cancer, Corsello and his colleagues systematically tested 4,518 compounds from the DRH (of which 3,350 are already approved for use in the U.S. or Europe) against 578 cancer cell lines. Most were developed to treat diseases other than cancer; about a quarter were originally developed for cancer. Using a molecular bar-coding method to keep track of the vast array of cancer cell lines, which employs short sequences of DNA as \u201cbar codes,\u201d the researchers were able to test multiple cancer cell types simultaneously in each Petri dish, speeding the process considerably. In total, the team identified nearly 50 compounds that killed cancer cells and left other cells unscathed.\n\nThe researchers found 11 different drugs that trigger the same cancer-killing mechanism. These included one previously approved to treat essential thrombocytosis\u2014a blood disorder\u2014as well as progesterone medications. The drugs all appear to work by inducing an interaction between two proteins: PDE3A, which plays a role in regulating blood pressure, and SLFN12, whose role is not well understood. (In contrast, many existing cancer treatments merely inhibit enzymes.) Corsello says the interaction is \u201can attractive target\u201d for developing new therapies. \u201cThe drugs we found are a nice starting point to do that,\u201d he adds.\n\nOnce a drug shows selective anticancer effects, the next step is to find out how it works. Corsello says the team does so by looking at \u201ceverything that\u2019s known\u201d about the cancer cell lines the drug kills. He lists a battery of genomic features the researchers analyze to determine where and how the killing blow lands, including gene expression, mutation and the number of copies of the gene in the genotype. \u201cThen, using predictive modeling approaches, [we] determine predictive biomarkers of response to each of these therapies,\u201d he says.\n\nOf course, not all of these medications will turn out to work against cancer in humans. Predictive biomarkers can indicate how effective a treatment will be against a particular type of cancer cell line in the lab or how well it can treat a patient in the clinic. \u201cWe prioritized drugs for follow-up that had selective [anticancer] activity and drugs that had predictive biomarkers from these cell line features,\u201d Corsello says. Medications that can predictably kill certain cancer cells could eventually be tested in patients and predict individuals who could benefit from those treatments.\n\nCorsello says that the research team plans to add 300 new cancer cell lines and 300 drug compounds to the library. \u201cI think there\u2019s still a lot that remains to be learned and discovered from this data,\u201d Corsello says. By using technologies such as CRISPR gene editing and screening, \u201cwe\u2019re able to take a drug with promising activity and actually figuring out how it\u2019s working, which I think is a really promising strategy for the future that may have an impact on drug development.\u201d",
    "source_url": "www.scientificamerican.com",
    "bias_text": "center",
    "ID": "dmbib4SfZ3LJLJ1W"
}